1571 related articles for article (PubMed ID: 22080879)
1. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
2. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
4. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
6. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner.
Rattan R; Giri S; Hartmann LC; Shridhar V
J Cell Mol Med; 2011 Jan; 15(1):166-78. PubMed ID: 19874425
[TBL] [Abstract][Full Text] [Related]
7. PDCD6 additively cooperates with anti-cancer drugs through activation of NF-κB pathways.
Park SH; Lee JH; Lee GB; Byun HJ; Kim BR; Park CY; Kim HB; Rho SB
Cell Signal; 2012 Mar; 24(3):726-33. PubMed ID: 22142513
[TBL] [Abstract][Full Text] [Related]
8. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
9. Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway.
Cui Y; Zhou J; Rong F
Biochem Biophys Res Commun; 2020 Dec; 533(4):665-671. PubMed ID: 33051060
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
Premkumar DR; Arnold B; Jane EP; Pollack IF
Mol Carcinog; 2006 Jan; 45(1):47-59. PubMed ID: 16267832
[TBL] [Abstract][Full Text] [Related]
11. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
12. Activation of AMPK α2 inhibits airway smooth muscle cells proliferation.
Liu L; Pan Y; Song Y; Su X; Ke R; Yang L; Gao L; Li M
Eur J Pharmacol; 2016 Nov; 791():235-243. PubMed ID: 27600020
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45.
Osaki M; Kase S; Adachi K; Takeda A; Hashimoto K; Ito H
J Cancer Res Clin Oncol; 2004 Jan; 130(1):8-14. PubMed ID: 14605879
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines.
Wang L; Wu J; Lu J; Ma R; Sun D; Tang J
Mol Med Rep; 2015 Feb; 11(2):931-9. PubMed ID: 25355053
[TBL] [Abstract][Full Text] [Related]
15. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
16. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.
Altomare DA; Wang HQ; Skele KL; De Rienzo A; Klein-Szanto AJ; Godwin AK; Testa JR
Oncogene; 2004 Jul; 23(34):5853-7. PubMed ID: 15208673
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
18. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
19. Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells
Tang JC; An R; Jiang YQ; Yang J
Cancer Res Treat; 2017 Jul; 49(3):778-789. PubMed ID: 27857021
[TBL] [Abstract][Full Text] [Related]
20. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway.
Feng N; Luo J; Guo X
Mol Med Rep; 2016 Apr; 13(4):3243-8. PubMed ID: 26936429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]